Continuum Advisory’s Halozyme HALO Stock Holding History

Continuum Advisory’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28	Closed	-$1.47K	–	1962
2024 Q2	$1.47K	Sell	28 -43	-61%	-$1.89K	﹤0.01%	1382
2024 Q1	$3.11K	Buy	+71	New	+$2.66K	﹤0.01%	1178

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Continuum Advisory's HALO Position: Q3 2024 in Review

Continuum Advisory sold out of Halozyme (HALO) in Q3 2024, closing a stake of 28 shares — an estimated $1.47K sold.

Continuum Advisory first reported a position in HALO in Q1 2024 and held it in 2 quarters. The position peaked at $3.11K in Q1 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q3 2024.

Continuum Advisory reported no remaining Halozyme position as of Q3 2024 after selling out during the quarter.
Continuum Advisory sold 28 Halozyme shares in Q3 2024, an estimated $1.47K.
Continuum Advisory first reported a position in Halozyme in Q1 2024 and held it in 2 quarters.
Continuum Advisory's Halozyme position peaked at $3.11K in Q1 2024.
508 funds tracked by Wall St. Rank held Halozyme as of Q3 2024.

Based on Continuum Advisory's 13F filing for Q3 2024, filed 15 Nov 2024.